Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.

Singh S, Loke YK, Enright P, Furberg CD.

Thorax. 2013 Jan;68(1):114-6. doi: 10.1136/thoraxjnl-2011-201275. Epub 2012 Jul 4. Review.

PMID:
22764216
2.

Republished: pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.

Singh S, Loke YK, Enright P, Furberg CD.

Postgrad Med J. 2014 Apr;90(1062):205-7. doi: 10.1136/postgradmedj-2011-201275rep.

PMID:
24643260
3.

A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD.

Hilleman DE, Malesker MA, Morrow LE, Schuller D.

Int J Chron Obstruct Pulmon Dis. 2009;4:253-63. Epub 2009 Jul 20. Review.

4.

Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence.

Salpeter SR.

Drugs. 2009 Oct 22;69(15):2025-33. doi: 10.2165/11318580-000000000-00000.

PMID:
19791824
5.

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Singh S, Loke YK, Furberg CD.

JAMA. 2008 Sep 24;300(12):1439-50. doi: 10.1001/jama.300.12.1439. Review. Erratum in: JAMA. 2009 Mar 25;301(12):1227-30.

PMID:
18812535
6.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
7.

Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.

Keating GM.

Drugs. 2012 Jan 22;72(2):273-300. doi: 10.2165/11208620-000000000-00000. Review.

PMID:
22217233
8.

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials.

Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS.

Thorax. 2013 Jan;68(1):48-56. doi: 10.1136/thoraxjnl-2012-201926. Epub 2012 Oct 6. Review.

PMID:
23042705
9.

Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.

Tashkin DP.

Expert Rev Respir Med. 2010 Jun;4(3):279-89. doi: 10.1586/ers.10.23. Review.

PMID:
20524910
10.

Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis.

Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA.

Respir Med. 2009 Oct;103(10):1421-9. doi: 10.1016/j.rmed.2009.05.020. Epub 2009 Jun 24. Review.

11.

Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety.

Tashkin DP.

Curr Opin Pulm Med. 2010 Mar;16(2):97-105. doi: 10.1097/MCP.0b013e328335df1e. Review.

PMID:
20019615
12.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators.

N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

13.

Tiotropium Respimat inhaler and the risk of death in COPD.

Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators.

N Engl J Med. 2013 Oct 17;369(16):1491-501. doi: 10.1056/NEJMoa1303342. Epub 2013 Aug 30.

14.

Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.

Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP; UPLIFT Study Investigators.

Am J Respir Crit Care Med. 2009 Nov 15;180(10):948-55. doi: 10.1164/rccm.200906-0876OC. Epub 2009 Sep 3.

PMID:
19729663
15.

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.

Ann Intern Med. 2007 Apr 17;146(8):545-55. Epub 2007 Feb 19.

PMID:
17310045
16.

Cardiovascular safety of tiotropium in patients with COPD.

Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP.

Chest. 2010 Jan;137(1):20-30. doi: 10.1378/chest.09-0011. Epub 2009 Jul 10.

PMID:
19592475
17.

Tiotropium HandiHaler in the treatment of COPD: a safety review.

Kesten S, Celli B, Decramer M, Leimer I, Tashkin D.

Int J Chron Obstruct Pulmon Dis. 2009;4:397-409. Epub 2009 Nov 29. Review.

18.

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials.

Cooper CB, Anzueto A, Decramer M, Celli B, Tashkin DP, Leimer I, Kesten S.

Int J Chron Obstruct Pulmon Dis. 2011;6:269-75. doi: 10.2147/COPD.S17864. Epub 2011 May 9.

19.

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

Halpin DM, Dahl R, Hallmann C, Mueller A, Tashkin D.

Int J Chron Obstruct Pulmon Dis. 2015 Feb 5;10:239-59. doi: 10.2147/COPD.S75146. eCollection 2015.

20.
Items per page

Supplemental Content

Write to the Help Desk